219 related articles for article (PubMed ID: 34496490)
1. [Clinicopathological features of malignant mixed mesodermal tumor: analysis of 50 cases].
Ding XH; Ma ZY; Wang YF; Dou FX; Yuan J; Tian X; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1008-1013. PubMed ID: 34496490
[No Abstract] [Full Text] [Related]
2. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
Mikami Y; Hata S; Kiyokawa T; Manabe T
Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
[TBL] [Abstract][Full Text] [Related]
3. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
4. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
5. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
6. The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma.
Tong SY; Lee JM; Choi YJ; Lee JK; Kim JW; Cho CH; Kim SM; Park SY; Park CY; Kim KT
Aust N Z J Obstet Gynaecol; 2012 Feb; 52(1):44-8. PubMed ID: 22188343
[TBL] [Abstract][Full Text] [Related]
7. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype.
Oliva E; Clement PB; Young RH
Adv Anat Pathol; 2000 Sep; 7(5):257-81. PubMed ID: 10976906
[TBL] [Abstract][Full Text] [Related]
8. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.
Bland AE; Stone R; Heuser C; Shu J; Jazaeri A; Shutter J; Atkins K; Rice L
Int J Gynecol Cancer; 2009 Feb; 19(2):261-5. PubMed ID: 19396006
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].
Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Le Frere Belda MA; Averous G; Leroux A; Bataillon G; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
Bull Cancer; 2024 Jan; 111(1):97-116. PubMed ID: 37806863
[TBL] [Abstract][Full Text] [Related]
11. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
[No Abstract] [Full Text] [Related]
12. [Primary ovarian malignant mixed mesodermal tumor (MMMT) as a second primary tumor in a patient with invasive breast carcinoma--case report].
Sentija K; Bolanca IK; Simon SK; Kukura V; Skrtić A; Gasparov S
Acta Med Croatica; 2011 Sep; 65 Suppl 1():229-34. PubMed ID: 23126058
[TBL] [Abstract][Full Text] [Related]
13. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
14. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
[TBL] [Abstract][Full Text] [Related]
15. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
16. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
17. [Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report].
Ning BH; Zhang QX; Yang H; Dong Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):366-369. PubMed ID: 37042152
[TBL] [Abstract][Full Text] [Related]
18. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.
Ambros RA; Sherman ME; Zahn CM; Bitterman P; Kurman RJ
Hum Pathol; 1995 Nov; 26(11):1260-7. PubMed ID: 7590702
[TBL] [Abstract][Full Text] [Related]
19. Epithelioid endometrial and endometrioid stromal tumors: a report of four cases emphasizing their distinction from epithelioid smooth muscle tumors and other oxyphilic uterine and extrauterine tumors.
Oliva E; Clement PB; Young RH
Int J Gynecol Pathol; 2002 Jan; 21(1):48-55. PubMed ID: 11781523
[TBL] [Abstract][Full Text] [Related]
20. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
